Combination of low- or moderate-intensity statin and ezetimibe vs. high-intensity statin monotherapy on primary prevention of cardiovascular disease and all-cause death: a propensity-matched nationwide cohort study.
Ji Eun JunIn-Kyung JeongKyu Jeong AhnHo Yeon ChungYou Cheol HwangPublished in: European journal of preventive cardiology (2024)
Among people without pre-existing CVD, moderate-intensity statin with ezetimibe combination was superior to high-intensity statin monotherapy in preventing composite outcomes as well as each of MI and stroke. In contrast, low-intensity statin with ezetimibe combination reduced the risk of composite but not individual outcomes.
Keyphrases
- high intensity
- cardiovascular disease
- coronary artery disease
- resistance training
- low density lipoprotein
- type diabetes
- combination therapy
- cardiovascular events
- magnetic resonance
- cardiovascular risk factors
- randomized controlled trial
- open label
- metabolic syndrome
- clinical trial
- adipose tissue
- skeletal muscle
- body composition
- weight loss
- blood brain barrier
- study protocol
- contrast enhanced